In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roivant Sciences raises $200mm in private placement

Executive Summary

Roivant Sciences GMBH raised $200mm in a private placement financing ($7bn post-money valuation) with new investors NovaQuest Capital Management, RTW Investments and other large institutional asset managers. All previous institutional shareholders also participated in the financing. The company will use the offering proceeds to launch additional "Vants" (entrepreneurial biotech and healthcare tech companies) for innovative medicines and technologies. Since Roivant's last financing in 2017, the company has grown its therapies in development from 14 to 34 and its Vants from 6 to 14.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies